Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research

News provided by

www.transparencymarketresearch.com

Jul 25, 2014, 10:30 ET

ALBANY, New York, July 25, 2014 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) - Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume), 2013 - 2019", the global insulin market was valued at USD 19.99 billion in 2012 and is expected to grow at a CAGR of 6.1% from 2013 to 2019 to reach USD 32.24 billion in 2019.

Browse the full Global and China Insulin Market Report with TOC at http://www.transparencymarketresearch.com/insulin-market.html

Rising prevalence of diabetes is one of the serious healthcare concerns on a global level. Insulin is a hormone secreted by pancreas to absorb the blood sugar. However, in diabetes, it is either not possible for the body to secrete insulin (type-1) or to utilize secreted insulin to metabolize glucose (type-2). Insulin deficiency in diabetic patients is the most important factor driving the insulin market globally.  Rising prevalence of diabetes and extensive R&D activities are the other key factors boosting growth in the insulin market. No permanent cure has been invented for diabetes, thus the evolution of insulin therapy has emerged as an indispensible treatment therapy for type-1 diabetes patients.

The global and China insulin market is segmented based on source and mode of action. The insulin market by source is categorized as modern insulin and human insulin. The modern insulin segment is expected to grow at the fastest rate during the forecast period from 2013 to 2019, globally as well as in China. The insulin market by mode of action is segmented into rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Due to advantages over other derivatives, the long-acting derivatives segment is expected to grow rapidly during the forecast period. The segment held the largest share of 42.77% of the total market in 2012. It is expected to be the largest segment by the end of 2019. Rapid-acting insulin was the second largest segment in 2012. Other segments such as premixed, intermediate-acting and short-acting insulin derivatives are expected to lose market share during the forecast period. This is mainly due to low patient preference and lack of R&D in these segments. Pharmaceutical companies have concentrated their R&D strategies towards long-acting and rapid-acting derivatives development, which would boost market growth.

Browse All Market Research Press Releases at: http://www.transparencymarketresearch.com/press-releases.htm

The rapid-acting, long-acting and premixed derivatives segments are the most important segments in China. Growth in these segments is mainly attributed to rising population of type-1 diabetes and growing tendency of type-2 diabetes patients to use insulin as a therapeutic agent.

The insulin market in China is expected to grow steadily due to extensive R&D activities for the development of new insulin analogs and formulations that can be administered via different routes. Various products such as LY2605541 (Eli Lilly and Company), MK-1293 (Merck & Co., Inc.), NN1218 (Novo Nordisk A/S) and Afrezza (MannKind Corporation) are under pipeline studies and are expected to enter the market during the forecast period. Due to these new formulations, the market is likely to grow steadily during the forecast period.

The insulin market is highly consolidated and dominated by select players operating on a global level such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi. In China, local and regional players such as Shanghai Fosun Pharmaceuticals Pvt. Ltd. and Tonghua Dongbao also contribute to the insulin market.

Related & Recently Published Reports by Transparency Market Research 

The global and China insulin market is segmented as follows: 

  • Global and China Insulin Market, by Mode of Action 
    • Rapid-Acting
    • Short-Acting
    • Intermediate-Acting
    • Premixed
    • Long-Acting

Browse the full Global and China Insulin Market Report with TOC at http://www.transparencymarketresearch.com/insulin-market.html

  • Global and China Insulin Market, by Source 
    • Modern Insulin
    • Human Insulin

Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us  

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact 

Ms. Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: [email protected]

Website: http://www.transparencymarketresearch.com/

Company Blog: http://www.tmrblog.com/

Blog: http://transparencymarketresearch.areavoices.com/

Browse Press Release of Global and China Insulin Market at @ http://www.transparencymarketresearch.com/pressrelease/insulin-market.htm

SOURCE www.transparencymarketresearch.com

21%

more press release views with 
Request a Demo